Sentences with phrase «pembrolizumab resulted»

Not exact matches

Researchers are currently testing pembrolizumab to determine if it has the same result in other cancers, as well as trying to combine pembrolizumab with other therapies.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of therapy.

We are currently waiting for the results of several trials including EORTC 1325 which is investigating pembrolizumab, a PD - 1 checkpoint blocking antibody, compared to placebo in the adjuvant setting.»

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Pembrolizumab, marketed under the name Keytruda, was well tolerated by both cohorts at a 200 mg dose every three weeks, according to study results.

These results support the use of pembrolizumab as the new standard of care for advanced bladder cancer,» concluded Dr Necchi.

Dr Butler said: «Our results show that patients benefited from pembrolizumab regardless of whether or not they had been pre-treated with ipilimumab.»

Reporting the results from three trials of pembrolizumab for patients with advanced melanoma, Dr Marcus Butler, a medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada, told ECCO2017 that 84 of the 1567 patients in the KEYNOTE - 001, 002 and 006 studies had advanced mucosal melanoma.

Results of the EORTC 1325 - MG / Keynote 054 phase III trial: Alexander Eggermont discussed «Pembrolizumab versus place... https://t.co/1faoqTk4vZ

Zakharia, who presented the data at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, reveals the overall response data from the trial, toxicity data, and compares the results to historical data of pembrolizumab monotherapy from KEYNOTE - 006, which included similar patients.

Naiyer Rizvi, M.D., of Memorial Sloan Kettering, presented results of pembrolizumab in lung cancer.

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.

Tanguy Seiwert, M.D., of The University of Chicago, presented results of a phase 1b trial of Merck's pembrolizumab in a cohort of patients with advanced head and neck cancer.

May 29, 2015 Pembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical OncPembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncpembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology (ASCO).

At AACR 2018, Dr. Alexander Eggermont presented results of KEYNOTE - 045 / EORTC 1325 - MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.